The Basic Science of Platelet-rich Plasma (PRP): What Clinicians Need to Know

被引:84
作者
Arnoczky, Steven P. [1 ]
Shebani-Rad, Shahin [2 ]
机构
[1] Michigan State Univ, Coll Vet Med, Lab Comparat Orthopaed Res, E Lansing, MI 48824 USA
[2] Michigan State Univ, McLaren Flint, Dept Orthopaed Surg, Flint, MI USA
关键词
platelet-rich plasma; white blood cells; bioactive factors; thrombin; fibrin matrices; GROWTH-FACTOR; INFLAMMATORY RESPONSE; IMMUNOLOGICAL IMPACT; IN-VITRO; FIBRIN; MATRIX; THROMBIN; MUSCLE; CLASSIFICATION; ACCUMULATION;
D O I
10.1097/JSA.0b013e3182999712
中图分类号
G8 [体育];
学科分类号
04 ; 0403 ;
摘要
Platelet-rich plasma (PRP) has been advocated for the biological augmentation of tissue healing and regeneration through the local introduction of increased levels (above baseline) of platelets and their associated bioactive molecules. In theory, the increased levels of autologous growth factors and secretory proteins provided by the concentrated platelets may enhance the wound healing process, especially in degenerative tissues or biologically compromised individuals. Although PRP has been increasingly utilized in the treatment of a variety of sports-related injuries, improvements in healing and clinical outcomes have not been universally reported. One reason for this may be the fact that all PRP preparations are not the same. Variations in the volume of whole blood taken, the platelet recovery efficacy, the final volume of plasma in which the platelets are suspended, and the presence or absence of white blood cells, and the addition of exogenous thrombin to activate the platelets or calcium chloride to induce fibrin formation, can all affect the character and potential efficacy of the final PRP product. This article will review the basic principles involved in creating PRP and examine the potential basic scientific significance of the individual blood components contained in the various forms of PRP currently used in sports medicine.
引用
收藏
页码:180 / 185
页数:6
相关论文
共 55 条
[41]   Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin [J].
Ortel, TL ;
Mercer, MC ;
Thames, EH ;
Moore, KD ;
Lawson, JH .
ANNALS OF SURGERY, 2001, 233 (01) :88-96
[42]  
Palmer DS, 1998, VOX SANG, V75, P115, DOI 10.1046/j.1423-0410.1998.7520115.x
[43]   Platelet-derived growth factor inhibits demineralized bone matrix-induced intramuscular cartilage and bone formation - A study of immunocompromised mice [J].
Ranly, DM ;
McMillan, J ;
Keller, T ;
Lohmann, CH ;
Meunch, T ;
Cochran, DL ;
Schwartz, Z ;
Boyan, BD .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2005, 87A (09) :2052-2064
[44]  
Sampson S, 2008, CURR REV MUSCULOSKE, V1, P165, DOI 10.1007/s12178-008-9032-5
[45]  
Schneider BSP, 2007, SPORTS MED, V37, P837
[46]   Exposure of mice to topical bovine thrombin induces systemic autoimmunity [J].
Schoenecker, JG ;
Johnson, RK ;
Lesher, AP ;
Day, JD ;
Love, SD ;
Hoffman, MR ;
Ortel, TL ;
Parker, W ;
Lawson, JH .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (05) :1957-1969
[47]   Efficacy of Autologous Platelet-Rich Plasma Use for Orthopaedic Indications: A Meta-Analysis [J].
Sheth, Ujash ;
Simunovic, Nicole ;
Klein, Guy ;
Fu, Freddie ;
Einhorn, Thomas A. ;
Schemitsch, Emil ;
Ayeni, Olufemi R. ;
Bhandari, Mohit .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2012, 94A (04) :298-307
[48]  
SPRUGEL KH, 1987, AM J PATHOL, V129, P601
[49]   CYTOKINE GENERATION IN STORED PLATELET CONCENTRATES [J].
STACK, G ;
SNYDER, EL .
TRANSFUSION, 1994, 34 (01) :20-25
[50]  
Steine-Martin EA, 1998, CLIN HEMATOLOGY PRIN